Scientists developed Evo 2, a large biological foundation model trained on about 9 trillion DNA base pairs that can analyse ...

Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected mid-2026Global pivotal Phase 3 ...

This Python project provides a means of running parallelized Widom's Test Particle Insertion Method [1] on all sorts of configurations drawn from molecular-dynamics or monte-carlo simulations. This ...

Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces the signing of a term sheet for a strategic asset ...

This tool is released under the GPL license to promote advancements in TE research. TEgenomeSimulator was developed by The New Zealand Institute for Plant and Food Research Ltd. More details about ...

Subcutaneous (SC) amivantamab reduces administration from hours to minutes, with efficacy and safety consistent with intravenous (IV) amivantamab1,2,3,4,5 SC amivantamab is now authorised across all ...

What Is It, and Why Does It Matter? Rybrevant Faspro is a new under-the-skin (subcutaneous, or SC) injection form of the anticancer medicine Rybrevant (amivantamab). The FDA has now approved it in ...

"A monthly dosing schedule offers patients convenience without sacrificing efficacy," said Danny Nguyen, M.D., Assistant Clinical Professor, Department of Medical Oncology & Therapeutics Research, ...

Patients with stage 4 lung cancer and EGFR mutations may benefit from combination therapies that improve disease control. The American Society of Clinical Oncology (ASCO) released updated treatment ...